Los Angeles Capital Management LLC Increases Stake in DexCom, Inc. (NASDAQ:DXCM)

Los Angeles Capital Management LLC lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 1,104.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 81,091 shares of the medical device company’s stock after purchasing an additional 74,360 shares during the period. Los Angeles Capital Management LLC’s holdings in DexCom were worth $6,306,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in DXCM. Private Advisor Group LLC grew its stake in shares of DexCom by 5.7% during the third quarter. Private Advisor Group LLC now owns 11,318 shares of the medical device company’s stock valued at $759,000 after buying an additional 608 shares during the last quarter. International Assets Investment Management LLC bought a new position in DexCom during the 3rd quarter worth approximately $930,000. Hennion & Walsh Asset Management Inc. increased its stake in DexCom by 15.1% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 4,409 shares of the medical device company’s stock worth $296,000 after purchasing an additional 579 shares during the period. State of Alaska Department of Revenue lifted its position in DexCom by 7.3% in the third quarter. State of Alaska Department of Revenue now owns 46,400 shares of the medical device company’s stock valued at $3,110,000 after purchasing an additional 3,155 shares during the last quarter. Finally, abrdn plc lifted its position in DexCom by 28.4% in the third quarter. abrdn plc now owns 384,646 shares of the medical device company’s stock valued at $25,842,000 after purchasing an additional 85,174 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on DXCM shares. Citigroup lifted their target price on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Morgan Stanley raised their target price on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Finally, Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average price target of $99.06.

DexCom Stock Performance

Shares of DexCom stock opened at $89.91 on Thursday. The business has a fifty day simple moving average of $84.29 and a two-hundred day simple moving average of $76.47. The firm has a market capitalization of $35.13 billion, a P/E ratio of 62.87, a P/E/G ratio of 2.30 and a beta of 1.14. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares of the company’s stock, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 38,083 shares of company stock valued at $3,309,794 in the last ninety days. 0.30% of the stock is currently owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.